LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Loss of Critical Enzyme Prevents Infection by Mutant Leishmania Parasite

By LabMedica International staff writers
Posted on 27 Jul 2010
Image: Colored scanning electron micrograph (SEM) of several Leishmania parasitic protozoans (Photo courtesy of the Eye of Science).
Image: Colored scanning electron micrograph (SEM) of several Leishmania parasitic protozoans (Photo courtesy of the Eye of Science).
A group of enzymes that are key regulators of cell growth, proliferation, and structure in eukaryotes has been cited as potential targets by drug developers seeking a cure for the parasitic disease leishmaniasis.

Leishmaniasis is a parasitic disease with cutaneous, mucocutaneous, and visceral clinical manifestations, depending on the Leishmania spp. and human host. Worldwide, there are some 350 million people at risk of contracting the disease, but current treatment options rely predominantly on outmoded pentavalent antimonials, which have the potential to cause serious systemic toxicity.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) searched genome databases and located the genes that encode three TOR (target of rapamycin) kinases in Leishmania major. In all eukaryotic organisms, these enzymes are linked to the regulation of critical cell events such as growth, proliferation, and structural maintenance.

The investigators attempted to engineer genetically L. major variants lacking the gene for one or more of the three TOR enzymes. They reported in the June 20, 2010, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that the parasite could not survive removal of the genes for either TOR kinase-1 or TOR kinase-2. On the other hand, removal of TOR kinase-3 (while leaving the other two intact) resulted in a slower growing mutant that maintained normal morphology, rapamycin sensitivity, and differentiation into the animal-infective promastigote stage. Significantly, these mutants were unable to survive or replicate in macrophages in vitro, or to induce pathology or establish infections in mice in vivo. The loss of virulence was associated with a defect in acidocalcisome formation, as this unique organelle was grossly altered in the TOR kinase -3 mutants and it no longer accumulated polyphosphates. The mutants also showed defects in osmoregulation and were sensitive to starvation for glucose but not amino acids.

Results of this study indicate that acidocalcisomes are essential for infection and may modulate the flow of fluids across the cell membrane or provide a mechanism for coping with stress and glucose depletion.

"If we can hit any of these proteins with a drug that will inhibit them, we should be able to strike a significant blow against Leishmania,” said senior author Dr. Stephen Beverley, professor of molecular microbiology at Washington University School of Medicine. "Given the numerous inhibitors already available, I think there is a pretty good chance that we will be able to identify a compound that specifically inhibits one of Leishmania's TOR kinases.”

Related Links:
Washington University School of Medicine



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more